Militia Capital Management LLC Takes $2.46 Million Position in National Health Investors, Inc. $NHI

Militia Capital Management LLC bought a new position in National Health Investors, Inc. (NYSE:NHI) in the first quarter, Holdings Channel reports. The firm bought 30,400 shares of the real estate investment trust’s stock, valued at approximately $2,458,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. NewEdge Advisors LLC increased its holdings in shares of National Health Investors by 28.7% in the first quarter. NewEdge Advisors LLC now owns 1,546 shares of the real estate investment trust’s stock worth $114,000 after purchasing an additional 345 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in National Health Investors by 9.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 249,937 shares of the real estate investment trust’s stock worth $18,460,000 after buying an additional 21,851 shares in the last quarter. Jane Street Group LLC increased its stake in shares of National Health Investors by 1,728.4% in the 1st quarter. Jane Street Group LLC now owns 69,697 shares of the real estate investment trust’s stock worth $5,148,000 after acquiring an additional 65,885 shares in the last quarter. Cetera Investment Advisers grew its stake in shares of National Health Investors by 6.1% in the second quarter. Cetera Investment Advisers now owns 4,792 shares of the real estate investment trust’s stock worth $336,000 after acquiring an additional 275 shares during the last quarter. Finally, American Century Companies Inc. grew its position in National Health Investors by 2.2% during the 2nd quarter. American Century Companies Inc. now owns 19,236 shares of the real estate investment trust’s stock valued at $1,349,000 after purchasing an additional 420 shares during the last quarter. 62.51% of the stock is owned by institutional investors.

National Health Investors Stock Down 1.3%

NYSE NHI opened at $80.04 on Thursday. National Health Investors, Inc. has a one year low of $67.94 and a one year high of $91.38. The company has a market capitalization of $3.88 billion, a P/E ratio of 25.82, a P/E/G ratio of 3.64 and a beta of 0.51. The stock has a 50 day moving average price of $74.80 and a 200-day moving average price of $79.69. The company has a debt-to-equity ratio of 0.83, a quick ratio of 8.20 and a current ratio of 8.20.

National Health Investors Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Tuesday, June 30th will be given a $0.92 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.68 dividend on an annualized basis and a yield of 4.6%. National Health Investors’s dividend payout ratio (DPR) is currently 118.71%.

Insider Activity

In other National Health Investors news, CEO D. Eric Mendelsohn bought 1,500 shares of the company’s stock in a transaction on Friday, June 5th. The stock was acquired at an average price of $68.84 per share, for a total transaction of $103,260.00. Following the completion of the transaction, the chief executive officer directly owned 133,316 shares of the company’s stock, valued at approximately $9,177,473.44. This represents a 1.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert A. Mccabe, Jr. purchased 890 shares of National Health Investors stock in a transaction dated Monday, June 15th. The stock was acquired at an average price of $71.65 per share, for a total transaction of $63,768.50. Following the completion of the acquisition, the director owned 44,159 shares of the company’s stock, valued at approximately $3,163,992.35. This trade represents a 2.06% increase in their position. The SEC filing for this purchase provides additional information. 2.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on NHI. Cantor Fitzgerald reiterated an “overweight” rating and set a $94.00 target price on shares of National Health Investors in a research note on Wednesday, April 22nd. Truist Financial lowered their price target on shares of National Health Investors from $89.00 to $81.00 and set a “buy” rating on the stock in a report on Friday, June 12th. BMO Capital Markets decreased their price target on National Health Investors from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Monday, June 15th. Zacks Research downgraded National Health Investors from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 25th. Finally, Wells Fargo & Company reduced their price objective on shares of National Health Investors from $84.00 to $79.00 and set an “equal weight” rating on the stock in a research report on Monday, June 1st. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $83.86.

National Health Investors Company Profile

National Health Investors, Inc (NYSE: NHI) is a specialized real estate investment trust (REIT) focused on owning and financing high-quality healthcare and senior housing facilities in the United States. The company’s portfolio encompasses a diverse range of properties, including skilled nursing centers, assisted living and memory care communities, behavioral health facilities, dialysis clinics, and medical office buildings. NHI typically enters into long-term net-lease agreements with experienced healthcare operators, providing stable and predictable rental income streams while enabling its tenants to concentrate on delivering quality care.

Since its founding in 1991 and initial public offering later that year, National Health Investors has pursued a disciplined growth strategy centered on strategic acquisitions, joint ventures, and selective development.